Suzetrigine vs Norco-postoperative Mohs Pain

May 7, 2026 updated by: Baylor Research Institute

Non-Opioid Pain Management After Mohs Reconstruction: An Investigator-Initiated, Prospective, Randomized Clinical Trial of Suzetrigine vs Hydrocodone/Acetaminophen

To compare suzetrigine versus hydrocodone/acetaminophen for postoperative pain control following dermatologic surgery.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

This study is a randomized, controlled trial that is evaluating the safety and efficacy of suzetrigine as a postoperative pain medication compared to the standard of care Hydrocodone/Acetaminophen in patients undergoing Mohs micrographic surgery (MMS) who are at high-risk for postoperative pain and opioid use. The goal is to reduce opioid prescription use and give patients a non-opioid pain medication option for particularly painful surgeries. Patients will be randomized into one of two groups, one group will receive the interventional medication and the other the standard of care medication.

Study Type

Interventional

Enrollment (Estimated)

75

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Texas
      • Dallas, Texas, United States, 75246
        • Baylor University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • adults between the age of 18-89
  • individuals who have a cutaneous tumor treated by MMS

Exclusion Criteria:

  • individuals younger than 18 and older than 89
  • individuals taking medications that interact with the CYP3A (Cytochrome P450 3A) pathway
  • individuals with liver disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Standard of Care
Participants will receive the standard of care drug Norco (a medicine that combines hydrocodone and acetaminophen).
Drug: Norco 5Mg-325Mg Tablet
Standard of care drug
Active Comparator: Control
Participants will receive the control drug, Suzetrigine.
Drug: Suzetrigine
Control Drug

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in need for opioid medication for pain management after Mohs micrographic surgery
Time Frame: 48hours post surgery
Change in mean visual analog scale (VAS; 0-10) pain scores at 24 and 48 hours after surgery with a minimal change in pain score of 1.0 points.
48hours post surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rescue pain management use
Time Frame: 48hours post surgery
Changes in need to use rescue medication for pain management
48hours post surgery
Adverse Events
Time Frame: 3 days after surgery
Evaluation of occurence of adverse events (irregular heart beat, abnormal blood pressure, change in consciousness, or need for urgent care or emergency room visit in the first 3 days after surgery).
3 days after surgery
Patient-reported adequacy of pain control
Time Frame: 48hours post surgery
Assessment of pain control with use of medication following surgery.
48hours post surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Baylor Research Institute

Investigators

  • Principal Investigator: Stan Tolkachjov, MD, Baylor Medical University Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 3, 2025

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

May 4, 2026

First Submitted That Met QC Criteria

May 4, 2026

First Posted (Actual)

May 8, 2026

Study Record Updates

Last Update Posted (Actual)

May 11, 2026

Last Update Submitted That Met QC Criteria

May 7, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 025-413

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cutaneous Tumors

Clinical Trials on Norco 5Mg-325Mg Tablet

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe